Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03798314 · ClinicalTrials.gov registry record · Phase 1
Nivolumab and Pomalidomide in Treating Patients With Relapsed or Refractory Central Nervous System Diffuse Large B Cell Lymphoma or Primary Vitreoretinal Diffuse Large B Cell Lymphoma
A Phase 1 study of Recurrent Nervous System Lymphoma and Recurrent Primary Vitreoretinal DLBCL, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
- 2
- Study locations
NCT03798314: Completed Phase 1 study of Recurrent Nervous System Lymphoma and Recurrent Primary Vitreoretinal DLBCL, sponsored by Mayo Clinic.
NCT03798314 is a Phase 1 study of Recurrent Nervous System Lymphoma and Recurrent Primary Vitreoretinal DLBCL that has completed, run by Mayo Clinic. The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03798314, a Phase 1 study of Recurrent Nervous System Lymphoma and Recurrent Primary Vitreoretinal DLBCL, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase I trials studies side effects and best dose of pomalidomide when given together with nivolumab in treating patients with primary central nervous system diffuse large B cell lymphoma or primary vitreoretinal diffuse large B cell lymphoma that has come back or that has not responded to treatment. Immunotherapy with monoclonal antibodies, such as pomalidomide and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Primary Outcome
The MTD in this study will be defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least one-third of patients (at least 2 of a maximum of 6 new patients).
Conditions Studied
Interventions
- BIOLOGICAL Nivolumab
- DRUG Pomalidomide
Study Locations (2)
Florida
- Mayo Clinic in Florida - Jacksonville
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2019-01-30 |
| Est. Completion | 2021-09-15 |
| Phase | Phase 1 |
What the finished NCT03798314 record still lists
NCT03798314 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 4 conditions, with Recurrent Nervous System Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT03798314 reports a single indexed study location in Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT03798314 about?
NCT03798314 is a clinical study titled "Nivolumab and Pomalidomide in Treating Patients With Relapsed or Refractory Central Nervous System Diffuse Large B Cell Lymphoma or Primary Vitreoretinal Diffuse Large B Cell Lymphoma". This phase I trials studies side effects and best dose of pomalidomide when given together with nivolumab in treating patients with primary central nervous system diffuse large B cell lymphoma or primary vitreoretinal diffuse large B cell lymphoma that has come back or that has not responded to trea...
What is the current status of trial NCT03798314?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2019-01-30. Estimated completion is 2021-09-15.
What conditions does trial NCT03798314 study?
This clinical trial studies the following conditions: Recurrent Nervous System Lymphoma, Recurrent Primary Vitreoretinal DLBCL, Refractory Nervous System Lymphoma, Refractory Primary Vitreoretinal DLBCL.
What interventions are being tested in trial NCT03798314?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Pomalidomide (DRUG).
Who is sponsoring clinical trial NCT03798314?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03798314 being conducted?
This trial has 2 study locations across Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03798314's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI